[ad_1]
FILE PHOTO: The logo of the Swiss drug manufacturer Roche is visible at its headquarters in Basel, Switzerland, on February 1, 2018. REUTERS / Arnd Wiegmann / File Photo
ZURICH (Reuters) – Roche (ROG.S) and Spark Therapeutics (ONCE.O) announced a further extension of the US $ 4.3 billion public takeover bid by the US gene therapy specialist in the United States and Great Britain.
The offer on Spark shares will continue until September 3, added Roche, adding that the terms of use were unchanged. "The parties remain committed to the transaction and work cooperatively and expeditiously with the Federal Trade Commission and the UK Competition and Markets Authority," said Roche.
Reportage of John Miller; Edited by Thomas Seythal
Our standards:The principles of Thomson Reuters Trust.
Source link
